Login / Signup

Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.

Juan Pablo AlderuccioIzidore S Lossos
Published in: Expert review of hematology (2023)
The lack of consistent genotyping profile in EMZL precludes the development of tissue and circulatory biomarkers for the diagnosis, risk stratification, and monitoring of minimal residual disease. Furthermore, the biological heterogeneity observed in extranodal sites associated with overall limited genomic data prevents the testing of druggable pathways aiming for a personalized treatment approach. Future clinical trials should focus on EMZL considering the unique clinical characteristics in the eligibility criteria and response assessment to better inform efficacy of novel agents and delineate sequences of therapies.
Keyphrases
  • clinical trial
  • genome wide
  • machine learning
  • single cell
  • combination therapy
  • dna methylation
  • high throughput
  • mouse model
  • extracorporeal membrane oxygenation
  • phase iii
  • phase ii